Pharsight

Biogen Inc. patents expiration

List of large molecules

1. List of Tysabri large molecules

Patent Number Company Patent Title Patent Expiry Activity Alert
US7157276 BIOGEN INC. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Jun, 2024

(2 months from now)

US7759117 BIOGEN INC. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Jun, 2024

(2 months from now)

US9709575 BIOGEN INC. Methods and products for evaluating an immune response to a therapeutic protein
Apr, 2026

(2 years from now)

US10705095 BIOGEN INC. Methods and products for evaluating an immune response to a therapeutic protein
Apr, 2026

(2 years from now)

US8871449 BIOGEN INC. Methods and products for evaluating an immune response to a therapeutic protein
Apr, 2026

(2 years from now)

US11292845 BIOGEN INC. Methods of treating inflammatory and autoimmune diseases with natalizumab
Feb, 2027

(2 years from now)

US10233245 BIOGEN INC. Methods of treating inflammatory and autoimmune diseases with natalizumab
Feb, 2027

(2 years from now)

US9493567 BIOGEN INC. Methods of treating inflammatory and autoimmune diseases with natalizumab
Mar, 2027

(2 years from now)

US8124350 BIOGEN INC. Methods and products for evaluating an immune response to a therapeutic protein
Aug, 2027

(3 years from now)

US9696307 BIOGEN INC. Methods for the detection of JC polyoma virus
Feb, 2030

(5 years from now)

US9005926 BIOGEN INC. Methods of preventing and removing trisulfide bonds
Oct, 2030

(6 years from now)

US9212379 BIOGEN INC. Nutrient monitoring and feedback control for increased bioproduct production
Nov, 2030

(6 years from now)

US9096879 BIOGEN INC. Method of supplementing culture media to prevent undesirable amino acid substitutions
Jan, 2031

(6 years from now)

US11287423 BIOGEN INC. Assay for JC virus antibodies
Jan, 2031

(6 years from now)

US10444234 BIOGEN INC. Assay for JC virus antibodies
Jan, 2031

(6 years from now)

US8318416 BIOGEN INC. Nutrient monitoring and feedback control for increased bioproduct production
Jan, 2031

(6 years from now)

US8809049 BIOGEN INC. Methods for producing mammalian cells
May, 2031

(7 years from now)

US9109015 BIOGEN INC. Method of isolating biomacromolecules using low pH and divalent cations
Aug, 2031

(7 years from now)

US9316641 BIOGEN INC. Assay for JC virus antibodies
Jan, 2032

(7 years from now)

US10308706 BIOGEN INC. Methods of preventing and removing trisulfide bonds
Feb, 2032

(7 years from now)

US10590454 BIOGEN INC. Methods of preventing and removing trisulfide bonds
May, 2032

(8 years from now)

US9790533 BIOGEN INC. Methods of preventing and removing trisulfide bonds
May, 2032

(8 years from now)

US9562252 BIOGEN INC. Methods of preventing and removing trisulfide bonds
May, 2033

(9 years from now)

US10119976 BIOGEN INC. Method of assessing risk of PML
May, 2034

(10 years from now)

US11280794 BIOGEN INC. Method of assessing risk of PML
May, 2034

(10 years from now)

US10677803 BIOGEN INC. Method of assessing risk of PML
May, 2034

(10 years from now)

US9994968 BIOGEN INC. Electrochemical etching apparatus
Aug, 2034

(10 years from now)

US10676772 BIOGEN INC. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
Aug, 2034

(10 years from now)

US10023831 BIOGEN INC. Gas delivery devices and associated systems and methods
Mar, 2035

(10 years from now)

US11124760 BIOGEN INC. Methods for overcoming glutamine deprivation during mammalian cell culture
Aug, 2035

(11 years from now)

US10844416 BIOGEN INC. Manganese supplementation for control of glycosylation in mammalian cell culture process
Jan, 2036

(11 years from now)

US11268119 BIOGEN INC. Copper supplementation for control of glycosylation in mammalian cell culture process
Feb, 2036

(11 years from now)

Ingredients: NATALIZUMAB